Susanna Naggie, MD, assistant professor of medicine (Infectious Diseases), has received an NIH Mentored Patient-Oriented Research Career Development Award (K23) to investigate the role of ART-induced lipoprotein increases on liver disease in HIV/HCV co-infected individuals.
Dr. Naggie's research focuses on a very high-risk patient population co-infected with HIV and HCV viruses. These patients are known to have more rapid progression of liver disease and therefore higher rates of cirrhosis and end-stage liver disease.
"Much of my research focuses on identifying factors that impact liver disease pathogenesis in this patient population, including the impact of antiretroviral medications," said Naggie. "The research is patient oriented and translational."
Naggie has also collaborated with David Goldstein, PhD, director of the Center for Human Genome Variation, investigating the role of pharmacogenomics in the individualized management of patients with HIV/HCV co-infection, including, the IL28B genetic polymorphism in treatment response and liver disease progression and the ITPA polymorphism in predicting anemia and how this associates with clinical outcomes.
"All of this work has an underlying theme which is to attempt to improve the care we provide these patients and to improve their clinical outcomes."
The objective of Naggie's K23 award will be achieved through several specific aims:
- Explore the association of antiretroviralinduced lipoprotein increases on HCV pathogenesis in HIV/HCV co-infected patients;
- Determine the effect of treatment with lipid lowering compounds on HCV pathogenesis in HIV/HCV co-infected patients;
- In a candidate gene approach investigate the IL28B genotype as a host baseline predictor for risk of ART-related lipoprotein increases and increased HCV viral load in HIV/HCV co-infected patients at months 6 and 12 following ART initiation;
- Determine the impact of the host genetics on differential ISG expression and lipoprotein biosynthesis in HIV/HCV co-infected patients at baseline and on pegIFN/RBV therapy.